MX2010010266A - Uso de pireno para llevar peptidos a traves de la barrera hematoencefalica. - Google Patents

Uso de pireno para llevar peptidos a traves de la barrera hematoencefalica.

Info

Publication number
MX2010010266A
MX2010010266A MX2010010266A MX2010010266A MX2010010266A MX 2010010266 A MX2010010266 A MX 2010010266A MX 2010010266 A MX2010010266 A MX 2010010266A MX 2010010266 A MX2010010266 A MX 2010010266A MX 2010010266 A MX2010010266 A MX 2010010266A
Authority
MX
Mexico
Prior art keywords
peptide
pyrene
agent
conjugate
seq
Prior art date
Application number
MX2010010266A
Other languages
English (en)
Spanish (es)
Inventor
Renee Wegrzyn
Andrew Nyborg
D Roxaneen Duan
Alan Rudolph
Original Assignee
Adlyfe Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adlyfe Inc filed Critical Adlyfe Inc
Publication of MX2010010266A publication Critical patent/MX2010010266A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056Peptides, proteins, polyamino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MX2010010266A 2008-03-21 2009-01-30 Uso de pireno para llevar peptidos a traves de la barrera hematoencefalica. MX2010010266A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3863408P 2008-03-21 2008-03-21
PCT/US2009/000613 WO2009117041A2 (en) 2008-03-21 2009-01-30 Use of pyrene to carry peptides across the blood brain barrier

Publications (1)

Publication Number Publication Date
MX2010010266A true MX2010010266A (es) 2010-12-14

Family

ID=40974375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010266A MX2010010266A (es) 2008-03-21 2009-01-30 Uso de pireno para llevar peptidos a traves de la barrera hematoencefalica.

Country Status (8)

Country Link
US (1) US20090238754A1 (enExample)
EP (1) EP2268314A2 (enExample)
JP (1) JP2011517666A (enExample)
CN (1) CN102014967A (enExample)
AU (1) AU2009226161A1 (enExample)
CA (1) CA2718860A1 (enExample)
MX (1) MX2010010266A (enExample)
WO (1) WO2009117041A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1395833B1 (en) 2001-05-31 2013-02-27 Adlyfe, Inc. Misfolded protein sensor method
US20050026165A1 (en) 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
EP2156181B1 (en) * 2006-07-28 2015-11-04 Adlyfe, Inc. Peptide probes for diagnostics and therapeutics
US20090274621A1 (en) * 2008-03-21 2009-11-05 Adlyfe, Inc Use of pyrene to carry non-peptide agents across the blood brain barrier
MX2011007916A (es) * 2009-01-30 2011-11-18 Adlyfe Inc Péptidos conformacionalmente dinámicos.
US20140328762A1 (en) * 2011-04-06 2014-11-06 Yiyi Zhang Fluorogenic Peptide Probes and Assays
EP2712425A2 (en) 2011-04-27 2014-04-02 Adlyfe, Inc. Ocular detection of amyloid proteins
JP6144673B2 (ja) 2011-06-03 2017-06-07 オフィディオン インコーポレイティド 血液脳関門を通過して輸送するための組成物及び方法
PL230602B1 (pl) 2013-04-04 2018-11-30 Centrum Badan Molekularnych I Makromolekularnych Polskiej Akademii Nauk Kwas (E)-3-arylo-3-oksoprop-1-enylo-2-fosfonowy i jego pochodne, sposob ich wytwarzania oraz ich zastosowanie
PL223918B1 (pl) 2013-05-28 2016-11-30 Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk 3-Arylo-2-fosforylo podstawione 1-indanony i sposób ich wytwarzania
EP3634978A1 (en) 2017-06-07 2020-04-15 Adrx, Inc. Tau aggregation inhibitors
EP3668886A2 (en) 2017-08-18 2020-06-24 Adrx, Inc. Tau aggregation peptide inhibitors
CN110759974B (zh) * 2018-07-25 2021-11-09 中国医学科学院药物研究所 一种磷脂-聚乙二醇-狂犬病毒衍生肽聚合物,其制备方法及应用
US10369170B1 (en) 2018-10-09 2019-08-06 Carol J. Buck Methods of treating basal cell carcinoma and glioblastoma
US10568907B1 (en) 2018-10-09 2020-02-25 Carol J. Buck Methods of treating basal cell carcinoma and glioblastoma
IL293545A (en) 2019-12-04 2022-08-01 Univ Leland Stanford Junior Enhancing blood-brain barrier drug transport by targeting endogenous regulators

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822733A (en) * 1985-05-28 1989-04-18 Amoco Corporation Lifetime-resolved assay procedures
US5260308A (en) * 1991-11-06 1993-11-09 Mayo Foundation For Medical Education And Research Method to increase permeability of the blood-nerve/brain barriers to proteins
US5604198A (en) * 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US5670477A (en) * 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
EP1003539A4 (en) * 1997-08-14 2002-09-11 Univ California AMYLOID beta-FLUORESCENT PEPTIDES AND USE THEREOF
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20030162698A1 (en) * 1999-01-27 2003-08-28 Alphonse Galdes Methods and compositions for treating dopaminergic and gaba-nergic disorders
AU2001249795A1 (en) * 2000-04-04 2001-10-15 Mayo Foundation For Medical Education And Research Methods for detecting plaques in vivo
US7311893B2 (en) * 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
US7470420B2 (en) * 2000-12-05 2008-12-30 The Regents Of The University Of California Optical determination of glucose utilizing boronic acid adducts
WO2002055547A2 (en) * 2001-01-10 2002-07-18 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services Sfrp and peptide motifs that interact with sfrp and methods of their use
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
WO2002094191A2 (en) * 2001-05-23 2002-11-28 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
US7851593B2 (en) * 2002-01-04 2010-12-14 Becton, Dickinson And Company Binding proteins as biosensors
JP2006510722A (ja) * 2002-01-29 2006-03-30 プロテミックス コーポレイション リミティド 細胞障害性タンパク質コンフォーマーの抑制
CA2542232A1 (en) * 2003-06-09 2005-01-20 Alnylam Pharmaceuticals, Inc. Method for treating neurodegenerative disease by inhibiting alpha-synuclein
US20050009109A1 (en) * 2003-07-08 2005-01-13 Stanford University Fluorophore compounds and their use in biological systems
US20060142227A1 (en) * 2003-10-14 2006-06-29 Itschak Lamensdorf Amphiphylic peptide-PNA conjugates for the delivery of PNA through the blood brain barrier
WO2005076732A2 (en) * 2004-02-17 2005-08-25 Kernel Biopharma Inc. Peptide-pna chimera targeting inducible nitric oxide synthase
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
AU2006214463B2 (en) * 2005-02-15 2012-08-30 Presympto, Inc. Method for detecting misfolded proteins and prions
US7951603B2 (en) * 2005-03-31 2011-05-31 The Noguchi Institute Method of mass spectrometric analysis of saccharides with aldehyde groups using labels containing a pyrene ring and a hydrazide group
US7388747B2 (en) * 2006-04-07 2008-06-17 Inventec Corporation Heat plate fixing structure
EP2156181B1 (en) * 2006-07-28 2015-11-04 Adlyfe, Inc. Peptide probes for diagnostics and therapeutics
US20090274621A1 (en) * 2008-03-21 2009-11-05 Adlyfe, Inc Use of pyrene to carry non-peptide agents across the blood brain barrier

Also Published As

Publication number Publication date
CN102014967A (zh) 2011-04-13
CA2718860A1 (en) 2009-09-24
WO2009117041A3 (en) 2010-01-07
JP2011517666A (ja) 2011-06-16
US20090238754A1 (en) 2009-09-24
EP2268314A2 (en) 2011-01-05
AU2009226161A1 (en) 2009-09-24
WO2009117041A2 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
US20090238754A1 (en) Use of pyrene to carry peptides across the blood brain barrier
US11939608B2 (en) Engineered heme-binding compositions and uses thereof
JP5097206B2 (ja) 診断および治療のためのペプチドプローブ
AU2010208181B2 (en) Conformationally dynamic peptides
US20090274621A1 (en) Use of pyrene to carry non-peptide agents across the blood brain barrier
US9795692B2 (en) Ocular detection of amyloid proteins
US20100267928A1 (en) Activatable diagnostic and therapeutic compound
US20120282169A1 (en) Detection and treatment of traumatic brain injury
Matharu et al. Gadolinium-complexed Aβ-binding contrast agents for MRI diagnosis of Alzheimer's Disease
US7871623B2 (en) Compositions and methods for imaging pain and stress in vivo
CN111182913A (zh) 用于通过多个生物屏障进行有效递送的方法和组合物
AU2015311836B2 (en) Methods for detecting amyloid beta oligomers
EP4245771A1 (en) Novel protein specifically binding to calreticulin and having human fibronectin domain iii scaffold and use thereof
KR20140042747A (ko) 줄기세포 검출을 위한 텔로머라제 유래 펩티드 및 조영물질의 컨쥬게이트 및 이를 포함하는 조영제

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration